Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Strategy for Locally Advanced Rectal Carcinoma
NCT01333709Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- May 2011
- Primary completion
- Sep 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of FOLFIRINOX, capecitabine in Rectal cancer (RC), sponsored by Institut du Cancer de Montpellier. Started May 2011; status: completed.
02
Drugs
FOLFIRINOXcapecitabine
03
Conditions
Rectal cancer (RC)
Beyond the preview
Go deeper on NCT01333709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333709.